{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T07:15:45Z","timestamp":1785741345766,"version":"3.56.0"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AR062920"],"award-info":[{"award-number":["R01 AR062920"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biofilm"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.bioflm.2023.100111","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T18:18:18Z","timestamp":1677694698000},"page":"100111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Biomaterial therapeutic strategies for treatment of bacterial lung infections"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7909","authenticated-orcid":false,"given":"Eunice","family":"Chee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-2518","authenticated-orcid":false,"given":"Andr\u00e9s J.","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioflm.2023.100111_bib1","series-title":"Causes of pneumonia","year":"2022"},{"issue":"10229","key":"10.1016\/j.bioflm.2023.100111_bib2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bioflm.2023.100111_bib3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.3389\/fmicb.2020.01434","article-title":"Secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics?","volume":"11","author":"Manohar","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bioflm.2023.100111_bib4","series-title":"COPD symptoms & causes","author":"Clinic","year":"2020"},{"key":"10.1016\/j.bioflm.2023.100111_bib5","series-title":"Cystic fibrosis: symptoms & causes","author":"Clinic","year":"2021"},{"issue":"7","key":"10.1016\/j.bioflm.2023.100111_bib6","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.bioflm.2023.100111_bib7","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.bioflm.2023.100111_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13568-021-01274-w","article-title":"The varying effects of antibiotics on gut microbiota","volume":"11","author":"Yang","year":"2021","journal-title":"Amb Express"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s11739-019-02208-y","article-title":"The lung microbiome: clinical and therapeutic implications","volume":"14","author":"Fabbrizzi","year":"2019","journal-title":"Internal and emergency medicine"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib10","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.201104-0655OC","article-title":"Topographical continuity of bacterial populations in the healthy human respiratory tract","volume":"184","author":"Charlson","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.bioflm.2023.100111_bib11","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1128\/JCM.01028-14","article-title":"Analysis of culture-dependent versus culture-independent techniques for identification of bacteria in clinically obtained bronchoalveolar lavage fluid","volume":"52","author":"Dickson","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41385-019-0160-6","article-title":"Microbes, metabolites, and the gut\u2013lung axis","volume":"12","author":"Dang","year":"2019","journal-title":"Mucosal Immunol"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib13","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1128\/JCM.00035-14","article-title":"Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease","volume":"52","author":"Huang","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"3","key":"10.1016\/j.bioflm.2023.100111_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41385-020-0270-1","article-title":"Host responses to mucosal biofilms in the lung and gut","volume":"13","author":"Domingue","year":"2020","journal-title":"Mucosal Immunol"},{"issue":"9","key":"10.1016\/j.bioflm.2023.100111_bib15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrmicro2415","article-title":"The biofilm matrix","volume":"8","author":"Flemming","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"6327","key":"10.1016\/j.bioflm.2023.100111_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1126\/science.aaj2191","article-title":"Antibiotic tolerance facilitates the evolution of resistance","volume":"355","author":"Levin-Reisman","year":"2017","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib17","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro.2017.42","article-title":"Persistent bacterial infections and persister cells","volume":"15","author":"Fisher","year":"2017","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib18","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1165\/rcmb.2017-0321TR","article-title":"Pseudomonas aeruginosa biofilms: host response and clinical implications in lung infections","volume":"58","author":"Maurice","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.bioflm.2023.100111_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21748-6","article-title":"Biofilm formation in the lung contributes to virulence and drug tolerance of Mycobacterium tuberculosis","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Nat Commun"},{"issue":"657","key":"10.1016\/j.bioflm.2023.100111_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo7793","article-title":"The past, present, and future of antibiotics","volume":"14","author":"Cook","year":"2022","journal-title":"Sci Transl Med"},{"issue":"11","key":"10.1016\/j.bioflm.2023.100111_bib21","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.tim.2016.06.009","article-title":"Antibiotic adjuvants: rescuing antibiotics from resistance","volume":"24","author":"Wright","year":"2016","journal-title":"Trends Microbiol"},{"issue":"12","key":"10.1016\/j.bioflm.2023.100111_bib22","article-title":"Probiotics for the prevention of Clostridium difficile\u2010associated diarrhea in adults and children","author":"Goldenberg","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.bioflm.2023.100111_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/antibiotics9030135","article-title":"Bacteriophage therapy: developments and directions","volume":"9","author":"Nikolich","year":"2020","journal-title":"Antibiotics"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00003088-200342040-00002","article-title":"Pharmacokinetic principles of bacteriophage therapy","volume":"42","author":"Payne","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.bioflm.2023.100111_bib25","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiy678","article-title":"Bacteriophage therapy increases complement-mediated lysis of bacteria and enhances bacterial clearance after acute lung infection with multidrug-resistant Pseudomonas aeruginosa","volume":"219","author":"Abd El-Aziz","year":"2019","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tim.2015.01.006","article-title":"Revisiting phage therapy: new applications for old resources","volume":"23","author":"Nobrega","year":"2015","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bioflm.2023.100111_bib27","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/978-3-319-41986-2_31","article-title":"Current updates from the long-standing phage research centers in Georgia, Poland, and Russia","author":"Mi\u0119dzybrodzki","year":"2021","journal-title":"Bacteriophage: Biology, Technology, Therapy"},{"issue":"2","key":"10.1016\/j.bioflm.2023.100111_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/bact.1.2.14590","article-title":"Pros and cons of phage therapy","volume":"1","author":"Loc-Carrillo","year":"2011","journal-title":"Bacteriophage"},{"issue":"7","key":"10.1016\/j.bioflm.2023.100111_bib29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/v10070351","article-title":"Resistance development to bacteriophages occurring during bacteriophage therapy","volume":"10","author":"Oechslin","year":"2018","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.bioflm.2023.100111_bib30","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-019-09629-x","article-title":"Bacteriophage-host arm race: an update on the mechanism of phage resistance in bacteria and revenge of the phage with the perspective for phage therapy","volume":"103","author":"Azam","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.bioflm.2023.100111_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118407","article-title":"Antimicrobial peptides\u2013Advances in development of therapeutic applications","volume":"260","author":"Luong","year":"2020","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.bioflm.2023.100111_bib32","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/ijms22020482","article-title":"Therapeutic potential of antimicrobial peptides in polymicrobial biofilm-associated infections","volume":"22","author":"Batoni","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib33","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/bip.10260","article-title":"Mode of action of membrane active antimicrobial peptides","volume":"66","author":"Shai","year":"2002","journal-title":"Peptide Science: Original Research on Biomolecules"},{"issue":"2","key":"10.1016\/j.bioflm.2023.100111_bib34","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13238-010-0004-3","article-title":"Alpha-helical cationic antimicrobial peptides: relationships of structure and function","volume":"1","author":"Huang","year":"2010","journal-title":"Protein & cell"},{"issue":"3","key":"10.1016\/j.bioflm.2023.100111_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/bip.20911","article-title":"Effects of net charge and the number of positively charged residues on the biological activity of amphipathic \u03b1\u2010helical cationic antimicrobial peptides","volume":"90","author":"Jiang","year":"2008","journal-title":"Peptide Science"},{"issue":"1","key":"10.1016\/j.bioflm.2023.100111_bib36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1128\/AAC.01619-12","article-title":"Two hits are better than one: membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin","volume":"57","author":"Yan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.bioflm.2023.100111_bib37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/bbrc.1998.8159","article-title":"Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions","volume":"244","author":"Park","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.bioflm.2023.100111_bib38","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/jam.14632","article-title":"Antibacterial action of lactoferricin B like peptide against Escherichia coli: reactive oxygen species\u2010induced apoptosis\u2010like death","volume":"129","author":"Lee","year":"2020","journal-title":"J Appl Microbiol"},{"issue":"12","key":"10.1016\/j.bioflm.2023.100111_bib39","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/nbt1267","article-title":"Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies","volume":"24","author":"Hancock","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.bioflm.2023.100111_bib40","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1016\/j.cub.2015.11.017","article-title":"Antimicrobial peptides","volume":"26","author":"Zhang","year":"2016","journal-title":"Curr Biol"},{"key":"10.1016\/j.bioflm.2023.100111_bib41","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3389\/fmicb.2017.01917","article-title":"Generation of persister cells of Pseudomonas aeruginosa and Staphylococcus aureus by chemical treatment and evaluation of their susceptibility to membrane-targeting agents","volume":"8","author":"Grassi","year":"2017","journal-title":"Front Microbiol"},{"issue":"423","key":"10.1016\/j.bioflm.2023.100111_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4044","article-title":"The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms","volume":"10","author":"de Breij","year":"2018","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.bioflm.2023.100111_bib43","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bbamem.2015.10.013","article-title":"Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria","volume":"1858","author":"Batoni","year":"2016","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"6","key":"10.1016\/j.bioflm.2023.100111_bib44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1099\/jmm.0.001000","article-title":"Antimicrobial peptides prevent bacterial biofilm formation on the surface of polymethylmethacrylate bone cement","volume":"68","author":"Volejn\u00edkov\u00e1","year":"2019","journal-title":"J Med Microbiol"},{"issue":"3","key":"10.1016\/j.bioflm.2023.100111_bib45","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/exd.12929","article-title":"Antimicrobial peptides and wound healing: biological and therapeutic considerations","volume":"25","author":"Mangoni","year":"2016","journal-title":"Exp Dermatol"},{"issue":"9","key":"10.1016\/j.bioflm.2023.100111_bib46","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3390\/antibiotics9090585","article-title":"The anti-microbial peptide (Lin-SB056-1) 2-K reduces pro-inflammatory cytokine release through interaction with Pseudomonas aeruginosa lipopolysaccharide","volume":"9","author":"Grassi","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.bioflm.2023.100111_bib47","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00018-013-1291-7","article-title":"Esculentin (1-21), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa","volume":"70","author":"Luca","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bioflm.2023.100111_bib48","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2147\/IDR.S217020","article-title":"Potential role of the antimicrobial peptide Tachyplesin III against multidrug-resistant P. aeruginosa and A. baumannii coinfection in an animal model","author":"Qi","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"7","key":"10.1016\/j.bioflm.2023.100111_bib49","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1021\/acs.jmedchem.1c02140","article-title":"Novel \u03b2-hairpin antimicrobial peptides containing the \u03b2-turn sequence of-RRRF-having high cell selectivity and low incidence of drug resistance","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.bioflm.2023.100111_bib50","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.3390\/ijms20225713","article-title":"Antimicrobial peptides as anti-infective agents in pre-post-antibiotic era?","volume":"20","author":"Ron\u010devi\u0107","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.bioflm.2023.100111_bib51","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1039\/D1NA00205H","article-title":"Inhaled antibiotic-loaded polymeric nanoparticles for the management of lower respiratory tract infections","volume":"3","author":"Sabuj","year":"2021","journal-title":"Nanoscale Adv"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/thoraxjnl-2016-208450","article-title":"Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis","volume":"72","author":"Stanojevic","year":"2017","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.bioflm.2023.100111_bib53","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1021\/acs.molpharmaceut.1c00491","article-title":"Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases","volume":"18","author":"Pramanik","year":"2021","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.bioflm.2023.100111_bib54","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.drudis.2020.07.018","article-title":"Recent advances in the development of microparticles for pulmonary administration","volume":"25","author":"Jain","year":"2020","journal-title":"Drug Discov Today"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib55","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/tde-2017-0037","article-title":"Drug delivery to the lungs: challenges and opportunities","volume":"8","author":"Newman","year":"2017","journal-title":"Ther Deliv"},{"key":"10.1016\/j.bioflm.2023.100111_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijbiomac.2020.12.083","article-title":"Connecting the dots in drug delivery: a tour d'horizon of chitosan-based nanocarriers system","volume":"169","author":"Pramanik","year":"2021","journal-title":"Int J Biol Macromol"},{"issue":"12","key":"10.1016\/j.bioflm.2023.100111_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261720","article-title":"Inhaled ciprofloxacin-loaded poly (2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections","volume":"16","author":"Sabuj","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bioflm.2023.100111_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2021.04.002","article-title":"Sustained release of peptides and proteins from polymeric nanocarriers produced by inverse Flash NanoPrecipitation","volume":"334","author":"Markwalter","year":"2021","journal-title":"J Contr Release"},{"key":"10.1016\/j.bioflm.2023.100111_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202102539","article-title":"Bacteriophage\u2010loaded poly (lactic\u2010co\u2010glycolic acid) microparticles mitigate Staphylococcus aureus infection and cocultures of Staphylococcus aureus and Pseudomonas aeruginosa","author":"Kalelkar","year":"2022","journal-title":"Advanced Healthcare Materials"},{"issue":"1\u20132","key":"10.1016\/j.bioflm.2023.100111_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2007.11.001","article-title":"Ciprofloxacin-encapsulated poly (DL-lactide-co-glycolide) nanoparticles and its antibacterial activity","volume":"352","author":"Jeong","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bioflm.2023.100111_bib61","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/IJN.S218966","article-title":"Antimicrobial peptide-loaded nanoparticles as inhalation therapy for Pseudomonas aeruginosa infections","volume":"15","author":"Falciani","year":"2020","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.bioflm.2023.100111_bib62","first-page":"997","article-title":"Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis","volume":"44","author":"Garg","year":"2016","journal-title":"Artif Cell Nanomed Biotechnol"},{"issue":"2","key":"10.1016\/j.bioflm.2023.100111_bib63","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jps.22775","article-title":"Liposomes coated with chitosan\u2013xanthan gum (chitosomes) as potential carriers for pulmonary delivery of rifampicin","volume":"101","author":"Manca","year":"2012","journal-title":"J Pharmaceut Sci"},{"issue":"1\u20132","key":"10.1016\/j.bioflm.2023.100111_bib64","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijpharm.2013.04.009","article-title":"Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity","volume":"449","author":"Osman","year":"2013","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.bioflm.2023.100111_bib65","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/02652048.2011.599437","article-title":"Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid","volume":"28","author":"Pourshahab","year":"2011","journal-title":"J Microencapsul"},{"key":"10.1016\/j.bioflm.2023.100111_bib66","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2014.10.022","article-title":"Inhaled formulations and pulmonary drug delivery systems for respiratory infections","volume":"85","author":"Zhou","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"issue":"30","key":"10.1016\/j.bioflm.2023.100111_bib67","doi-asserted-by":"crossref","first-page":"14341","DOI":"10.1039\/C6NR03256G","article-title":"Recent advances in chitosan-based nanoparticulate pulmonary drug delivery","volume":"8","author":"Islam","year":"2016","journal-title":"Nanoscale"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib68","volume":"14","author":"Abasalizadeh","year":"2020","journal-title":"J Biol Eng"},{"issue":"6","key":"10.1016\/j.bioflm.2023.100111_bib69","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/17425247.5.6.629","article-title":"Biodegradable polymeric nanocarriers for pulmonary drug delivery","volume":"5","author":"Rytting","year":"2008","journal-title":"Expet Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.bioflm.2023.100111_bib70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41551-018-0263-5","article-title":"Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections","volume":"2","author":"Agarwal","year":"2018","journal-title":"Nature biomedical engineering"},{"key":"10.1016\/j.bioflm.2023.100111_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113953","article-title":"Mesoporous silica nanoparticles for pulmonary drug delivery","volume":"177","author":"Garc\u00eda-Fern\u00e1ndez","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"38","key":"10.1016\/j.bioflm.2023.100111_bib72","doi-asserted-by":"crossref","first-page":"5066","DOI":"10.1002\/smll.201500937","article-title":"pH\u2010responsive isoniazid\u2010loaded nanoparticles markedly improve tuberculosis treatment in mice","volume":"11","author":"Hwang","year":"2015","journal-title":"Small"},{"key":"10.1016\/j.bioflm.2023.100111_bib73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.dib.2015.11.038","article-title":"Optimization of solid lipid nanoparticles prepared by a single emulsification-solvent evaporation method","volume":"6","author":"Pooja","year":"2016","journal-title":"Data Brief"},{"issue":"3","key":"10.1016\/j.bioflm.2023.100111_bib74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ejpb.2014.03.009","article-title":"Spray freeze drying for dry powder inhalation of nanoparticles","volume":"87","author":"Ali","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"issue":"43","key":"10.1016\/j.bioflm.2023.100111_bib75","doi-asserted-by":"crossref","first-page":"39648","DOI":"10.1021\/acsami.9b15118","article-title":"Bioinspired heteromultivalent ligand-decorated nanotherapeutic for enhanced photothermal and photodynamic therapy of antibiotic-resistant bacterial pneumonia","volume":"11","author":"Zhao","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"5","key":"10.1016\/j.bioflm.2023.100111_bib76","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1021\/acsnano.0c00269","article-title":"Size and charge adaptive clustered nanoparticles targeting the biofilm microenvironment for chronic lung infection management","volume":"14","author":"Gao","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.bioflm.2023.100111_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119505","article-title":"Hyaluronic acid and antimicrobial peptide-modified gold\/silver hybrid nanocages to combat bacterial multidrug resistance","volume":"586","author":"Yang","year":"2020","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib78","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11095-008-9562-y","article-title":"Role of particle size in phagocytosis of polymeric microspheres","volume":"25","author":"Champion","year":"2008","journal-title":"Pharmaceut Res"},{"issue":"5320","key":"10.1016\/j.bioflm.2023.100111_bib79","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bioflm.2023.100111_bib80","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere\u2122 technology","volume":"24","author":"Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"8","key":"10.1016\/j.bioflm.2023.100111_bib81","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1185\/03007995.2013.805122","article-title":"Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial","volume":"29","author":"Galeva","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bioflm.2023.100111_bib82","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin Drug Invest"},{"issue":"9","key":"10.1016\/j.bioflm.2023.100111_bib83","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1469-0691.2005.01217.x","article-title":"Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients","volume":"11","author":"Canton","year":"2005","journal-title":"Clinical microbiology and infection"},{"issue":"10","key":"10.1016\/j.bioflm.2023.100111_bib84","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1136\/thoraxjnl-2019-213037","article-title":"Nanotechnology based therapeutics for lung disease","volume":"74","author":"Doroudian","year":"2019","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.bioflm.2023.100111_bib85","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.bioflm.2023.100111_bib86","series-title":"Paper presented at: open forum infectious diseases","article-title":"Positive effect of liposomal amikacin for inhalation on Mycobacterium abcessus in cystic fibrosis patients","author":"Caimmi","year":"2018"},{"issue":"9","key":"10.1016\/j.bioflm.2023.100111_bib87","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.bioflm.2023.100111_bib88","series-title":"B14. Clinical trials across pulmonary disease","article-title":"Inhaled liposomal ciprofloxacin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection: results from two parallel phase III trials (ORBIT-3 and-4)","author":"Haworth","year":"2017"}],"container-title":["Biofilm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590207523000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590207523000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T04:02:47Z","timestamp":1762920167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590207523000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":88,"alternative-id":["S2590207523000084"],"URL":"https:\/\/doi.org\/10.1016\/j.bioflm.2023.100111","relation":{},"ISSN":["2590-2075"],"issn-type":[{"value":"2590-2075","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomaterial therapeutic strategies for treatment of bacterial lung infections","name":"articletitle","label":"Article Title"},{"value":"Biofilm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioflm.2023.100111","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100111"}}